A. Froidure (Bruxelles, Belgium), M. Afonso (Castelo Branco, Portugal)
Phenotypes of post covid interstitial lung disease; clinical, radiological, and pathological correlations.
L. Gori (Florence, Italy), C. Ravaglia (Forlì, Italy), V. Luzzi (Florence, Italy), L. Ciani (Florence, Italy), L. Giuntoli (Florence, Italy), G. Biadene (Florence, Italy), S. Bambina (Florence, Italy), M. Marinato (Florence, Italy), A. Dubini (Forlì, Italy), D. Cozzi (Florence, Italy), E. Cavigli (Florence, Italy), C. Comin (Florence, Italy), V. Pasini (Florence, Italy), S. Puglisi (Forlì, Italy), A. Cavazza (Reggio Emilia, Italy), V. Poletti (Forlì, Italy), M. Spinicci (Florence, Italy), A. Bartoloni (Florence, Italy), A. Peired (Florence, Italy), S. Ferraro (Florence, Italy), G. Papa (Florence, Italy), E. Berillo (Florence, Italy), C. Nardi (Florence, Italy), E. Rosi (Florence, Italy), F. Lavorini (Florence, Italy), S. Tomassetti (Florence, Italy)
|   |
Post-COVID interstitial lung disease in symptomatic patients after hospital discharge
L. Polivka (Budapest, Hungary), E. Barczi (Budapest, Hungary), T. Nagy (Budapest, Hungary), G. Horvath (Budapest, Hungary), A. Bohacs (Budapest, Hungary), V. Muller (Budapest, Hungary)
| |
COVID-19 in interstitial lung diseases: are fibrotic ILDs associated with worse outcomes?
M. Serino (Porto, Portugal), B. Martins (Porto, Portugal), M. Martins (Porto, Portugal), C. Valente (Porto, Portugal), I. Carvalho (Porto, Portugal), M. Barbosa (Barreiro-Montijo, Portugal), M. Alves (Lisboa, Portugal), C. Cascais (Aveiro, Portugal), A. Terras Alexandre (Porto, Portugal), N. Melo (Porto, Portugal), P. Caetano Mota (Porto, Portugal), A. Morais (Porto, Portugal), H. Novais-Bastos (Porto, Portugal)
| |
Non-Detection of Post Covid Pulmonary Fibrosis (PCPF) through HRCT and PFT but possible through Transbronchial Lung Biopsy
V. Tyagi (Meerut (Uttar Pradesh), India), S. Agarwal (Meerut (Uttar Pradesh), India), C. Dabral (Noida (Uttar Pradesh), India), M. Mittal (Ballarat,VIC 3350, Australia), M. Tyagi (Manglore, India)
| |
Post-COVID-19 Interstitial Lung Disease: a new entity, what do we deal with?
A. YUKSEL (Ankara, Turkey), D. Karadogan (Rize, Turkey), N. Hürsoy (Rize, Turkey), G. Telatar (Rize, Turkey), N. Köse (Bilecik, Turkey), F. Marim (Kütahya, Turkey), I. Kaya (Kütahya, Turkey), A. Er (Usak, Turkey), M. Erçelik (Afyonkarahisar, Turkey), D. Polat (Mersin, Turkey), M. Yumrukuz (Balikesir , Turkey), Ö. Gültekin (Erzurum, Turkey), C. I?lgar (Ankara, Turkey), S. Çakmakçi (Denizli, Turkey), B. Yilmaz Kara (Rize, Turkey), N. Özçelik (Rize, Turkey), I. Selimoglu (Rize, Turkey), K. Uyar Er (Rize, Turkey), A. Kotan (Rize, Turkey), H. Keskin (Rize, Turkey), M. Akgün (Erzurum, Turkey)
| |
Methylprednisolone in the treatment of post-COVID-19 Interstitial Lung Disease (STERCOV-ILD)
A. YUKSEL (Ankara, Turkey), D. Karadogan (Rize, Turkey), N. Hürsoy (Rize, Turkey), G. Telatar (Rize, Turkey), N. Köse (Bilecik, Turkey), F. Marim (Kütahya, Turkey), I. Kaya (Kütahya, Turkey), A. Er (Usak, Turkey), M. Erçelik (Afyonkarahisar, Turkey), D. Polat (Mersin, Turkey), M. Yumrukuz (Balikesir, Turkey), C. I?lgar (Ankara, Turkey), Ö. Gültekin (Erzurum, Turkey), S. Çakmakçi (Denizli, Turkey), B. Yilmaz Kara (Rize, Turkey), N. Özçelik (Rize, Turkey), I. Selimoglu (Rize, Turkey), K. Uyar Er (Rize, Turkey), A. Kotan (Rize, Turkey), H. Keskin (Rize, Turkey), M. Akgün (Erzurum, Turkey)
| |
Evolution of diffusion capacity in interstitial lung disease associated with rheumatoid arthritis
M. Vermant (Leuven, Belgium), T. Goos (Leuven, Belgium), H. Bode (Roeselare, Belgium), L. De Sadeleer (Leuven, Belgium), K. Verstraete (Leuven, Belgium), N. De Crem (Leuven, Belgium), E. De Langhe (Leuven, Belgium), A. Dubbeldam (Leuven, Belgium), E. Verbeken (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), B. Weynand (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), R. Westhovens (Leuven, Belgium), P. Verschueren (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
| |
Persistent Pneumonitis Post-COVID 19: description and risk factors
S. Cuerpo (Barcelona, Spain), F. Hernandez (Barcelona, Spain), M. Benegas (Barcelona, Spain), J. Francesqui (Barcelona, Spain), A. Lopez (Barcelona, Spain), R. Faner (Barcelona, Spain), N. Soler (Barcelona, Spain), S. Prieto (Barcelona, Spain), A. Vlagea (Barcelona, Spain), J. Barbera (Barcelona, Spain), M. Sanchez (Barcelona, Spain), J. Badia (Barcelona, Spain), O. Sibila (Barcelona, Spain), A. Agustí (Barcelona, Spain), J. Sellares (Barcelona, Spain), I. Cobo (Barcelona, Spain), A. Suarez (Barcelona, Spain), V. Torres (Barcelona, Spain), A. Salazar (Barcelona, Spain), A. Muñoz (Barcelona, Spain), L. Bravo (Barcelona, Spain), E. Ruiz (Barcelona, Spain), M. Molina (Barcelona, Spain), A. Soriano (Barcelona, Spain), J. García (Barcelona, Spain)
| |
Evaluation of pulmonary function in post-COVID-19 patients
V. Pejcic (Niš, Republic of Serbia), T. Pejcic (Niš, Republic of Serbia), M. Topalovic (Niš, Republic of Serbia), B. Božanic (Niš, Republic of Serbia), A. Ignjatovic (Niš, Republic of Serbia), D. Nastasijevic Borovac (Niš, Republic of Serbia)
| |
Bleomycin lung toxicity: a retrospective analysis of an old culprit.
D. Moreira Sousa (Covilhã, Portugal), M. Afonso (Covilhã, Portugal), S. Valente (Covilhã, Portugal)
| |
Interstitial lung disease in children associated with biological autoimmunity, analysis of a French monocentric retrospective cohort: towards IPAF in children?
L. Aoust (Paris, France), B. Bader-Meunier (Paris, France), C. Bodemer (Paris, France), A. Hadchouel-Duvergé (Paris, France)
| |
Effects of RXC007, a highly potent and selective ROCK2 inhibitor, in ex-vivo and in vivo models of pulmonary fibrosis.
A. Gambardella (Macclesfield, United Kingdom), N. Guisot (Macclesfield, United Kingdom), P. Bunyard (Macclesfield, United Kingdom), E. Offer (Macclesfield, United Kingdom)
| |
Diagnostic Performance of the Chest Interstitial Lung Disease Patient Questionnaire
T. Perluk (Tel Aviv, Israel), I. Friedman Regev (Tel Aviv, Israel), O. Freund (Tel Aviv, Israel), E. Kleinhendler (Tel Aviv, Israel), S. Ben-Ami (Tel Aviv, Israel), A. Bar-Shai (Tel Aviv, Israel), A. Unterman (Tel Aviv, Israel)
| |
A retrospective study exploring GAP index as a predictor of mortality in patients with Combined Pulmonary Fibrosis and Emphysema
H. Alsomali (Newcastle upon Tyne, United Kingdom)
| |
Early detection of interstitial lung disease using AI-powered spirometry
M. TOPALOVIC (Leuven, Belgium), T. Coenegrachts (Leuven, Belgium), S. Van Steenbergen (Leuven, Belgium), A. Halilovic (Leuven, Belgium), J. Maes (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), W. Janssens (Leuven, Belgium)
| |
Clusters of comorbidities in chronic hypersensitivity pneumonitis
T. Prior (Aarhus, Denmark), J. Wälscher (Heidelberg, Germany), B. Gross (Heidelberg, Germany), E. Bendstrup (Aarhus, Denmark), M. Kreuter (Heidelberg, Germany)
| |
Ultrasound as a potential tool to detect interstitial lung disease in the daily clinical setting of patients with rheumatoid arthritis
M. Gutierrez (Mexico City, Mexico), S. Ruta (La Plata, Argentina), D. Clavijo-Cornejo (Mexico City, Mexico), G. Fuentes-Moreno (Mexico City, Mexico), S. Reyes-Long (Mexico City, Mexico), C. Bertolazzi (Mexico City, Mexico)
| |
Cudetaxestat, a differentiated phase 2-ready investigational treatment for idiopathic pulmonary fibrosis
B. Elmankabadi (South San Francisco, United States), P. Ibrahim (South San Francisco, United States), C. Wong (South San Francisco, United States), R. Rajagopalan (South San Francisco, United States), X. Xu (South San Francisco, United States), W. Yu (South San Francisco, United States)
| |